Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Exploring the Different COVID Tests

On this episode of HealthFirst Talks, host Grace Huang welcomes two medical expert guests to discuss the different COVID-19 tests, their efficacy, and what test to use in different scenarios. Those guests are Dr. Scott Cohen, Chief Medical Information Officer and Chief Performance Improvement Officer for Bassett Healthcare Network, and Dr. Fiona Collins, dentist and…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from HealthFirst on MarketScale.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

On this episode of HealthFirst Talks, host Grace Huang welcomes two medical expert guests to discuss the different COVID-19 tests, their efficacy, and what test to use in different scenarios. Those guests are Dr. Scott Cohen, Chief Medical Information Officer and Chief Performance Improvement Officer for Bassett Healthcare Network, and Dr. Fiona Collins, dentist and international speaker and author.

Drs. Cohen and Collins explained the two types of COVID-19 tests: PCR tests and antigen tests. “There are two broad types of COVID-19 diagnostic tests. The antigen test takes the nasal fluid and looks for the presence of the antigen. If so, it’s positive. The PCR is looking for the presence of coronavirus RNA,” Dr. Cohen said.

Which is more accurate? Dr. Collins explained, “When looking at accuracy, diagnostic tests can be high sensitivity or high specificity. With high sensitivity, you have very few false negatives. With high specificity, very few false positives.”

The doctors agreed that false negatives were more concerning for COVID-19. With a false positive, the worst that could happen is isolation. A false negative could lead to spread.

When looking at the two tests, Dr. Collins shared, “PCR tests have high specificity and sensitivity. Antigen is only high specificity. It can have a false-negative rate of 15-20%.”

With this in mind, PCR testing is clearly the stronger test, but it may not always be the best choice. For post-exposure testing, Collins said, “PCR is more reliable, but it will take a few days to get back, so patients should quarantine until results.”

In the case of mass testing, the antigen test may be better because it acts as a monitoring system, and people are being tested regularly. “Antigen testing is fastest and least expensive. No lab is needed. Because you’re regular testing, you can overcome the sensitivity issue,” Dr. Cohen added.

Learn more about COVID testing and precautions to take by watching the conversation.

HealthFirst

Part of this channel

HealthFirst

Practice-ready solutions for dental and medical offices nationwide.

Visit the channel

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

Medicare will pay up to $137.53 per case in 2027 for BriefCase‑Triage

Medicare will pay up to $137.53 per case in 2027 for BriefCase‑Triage

Radiology Business reported Medicare will pay a maximum of $137.53 per case in 2027 for BriefCase-Triage. Holland & Knight said hospitals will be eligible for NTAP reimbursement for use of Aidoc’s CARE Body CT Multi-Triage beginning Oct. 1, 2026, with supplemental payments continuing for three years.

  • 01Radiology Business reported Medicare will pay a maximum of $137.53 per case in 2027 for BriefCase-Triage.
  • 02Holland & Knight said CMS approved an NTAP designation for Aidoc’s CARE Body CT Multi-Triage, with hospitals eligible for NTAP reimbursement beginning Oct. 1, 2026, with supplemental payments continuing for three years.

Sep 23, 2026

Blair Health raises CAD $4.24M to expand its LLM-guided specialty care workflows

Blair Health raises CAD $4.24M to expand its LLM-guided specialty care workflows

Blair Health raised CAD $4.24 million in a pre-seed round, according to Fierce Healthcare. It plans to expand protocol-driven virtual specialty care across Canada and the U.S.

  • 01Blair Health raised CAD $4.24 million in pre-seed funding.
  • 02Qualified Health positions its AI platform around safety and governance, including clinician oversight, auditability and traceability, according to Fierce Healthcare.

Sep 23, 2026

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512